Product Name :
THZ531
Description:
THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively.
CAS:
1702809-17-3
Molecular Weight:
558.07
Formula:
C30H32ClN7O2
Chemical Name:
(2E)-N-{4-[(3R)-3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}piperidine-1-carbonyl]phenyl}-4-(dimethylamino)but-2-enamide
Smiles :
CN(C)C/C=C/C(=O)NC1C=CC(=CC=1)C(=O)N1C[C@@H](CCC1)NC1N=C(C(Cl)=CN=1)C1=CNC2C=CC=CC=21
InChiKey:
RUBYHLPRZRMTJO-MOVYNIQHSA-N
InChi :
InChI=1S/C30H32ClN7O2/c1-37(2)15-6-10-27(39)34-21-13-11-20(12-14-21)29(40)38-16-5-7-22(19-38)35-30-33-18-25(31)28(36-30)24-17-32-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,22,32H,5,7,15-16,19H2,1-2H3,(H,34,39)(H,33,35,36)/b10-6+/t22-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Tapinarof} medchemexpress|{Tapinarof} Aryl Hydrocarbon Receptor|{Tapinarof} Protocol|{Tapinarof} In stock|{Tapinarof} manufacturer|{Tapinarof} Epigenetics}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively.|Product information|CAS Number: 1702809-17-3|Molecular Weight: 558.07|Formula: C30H32ClN7O2|Chemical Name: (2E)-N-{4-[(3R)-3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}piperidine-1-carbonyl]phenyl}-4-(dimethylamino)but-2-enamide|Smiles: CN(C)C/C=C/C(=O)NC1C=CC(=CC=1)C(=O)N1C[C@@H](CCC1)NC1N=C(C(Cl)=CN=1)C1=CNC2C=CC=CC=21|InChiKey: RUBYHLPRZRMTJO-MOVYNIQHSA-N|InChi: InChI=1S/C30H32ClN7O2/c1-37(2)15-6-10-27(39)34-21-13-11-20(12-14-21)29(40)38-16-5-7-22(19-38)35-30-33-18-25(31)28(36-30)24-17-32-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,22,32H,5,7,15-16,19H2,1-2H3,(H,34,39)(H,33,35,36)/b10-6+/t22-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 14.29 mg/mL (25.{{Baricitinib} web|{Baricitinib} JAK/STAT Signaling|{Baricitinib} Purity & Documentation|{Baricitinib} References|{Baricitinib} manufacturer|{Baricitinib} Cancer} 61 mM; Need ultrasonic).PMID:24516446 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|The results from Kinase assays demonstrate that THZ531 potently inhibits CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively; whereas inhibition of CDK7 and CDK9 is more than 50-fold weaker with IC50s of 8.5 and 10.5 µM, respectively. THZ531 treatment leads to a dramatic and irreversible decrease in Jurkat cell proliferation with an IC50 of 50 nM. FACS cell cycle analysis following treatment with escalating doses of THZ531 displays a dose and time-dependent increase in the number of cells exhibiting sub-G1 content. At 50 nM THZ531, no increase in the percentage of apoptotic cells is observed over DMSO control for the time course of the experiment. Higher doses of THZ531 leads to pronounced Annexin V signal with 30 to 40% annexin V-positively stained cells by 72 hrs. A dramatic reduction in elongating Pol II following THZ531 treatment is also observed.|Products are for research use only. Not for human use.|